ADC Therapeutics is expected to report Q3 2026 revenue of $22.52 million and an EPS loss of $0.21, with its current $3.45 share price trading significantly below the $8.50 average analyst price target.
Investors are primarily focused on the net product sales of Zynlonta and evidence of sustained commercial momentum in the relapsed/refractory diffuse large B-cell lymphoma market.
The company has recently emphasized cost-reduction measures and pipeline prioritization to extend its cash runway through late 2026. Management updates regarding the ongoing LOTIS-5 confirmatory trial and the ADCT-601 clinical program will be critical for determining the stock's future trajectory.